New Drugs in Cancer Chemotherapy

Nonfiction, Health & Well Being, Medical, Medical Science, Pharmacology, Specialties, Oncology
Cover of the book New Drugs in Cancer Chemotherapy by , Springer Berlin Heidelberg
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783642815652
Publisher: Springer Berlin Heidelberg Publication: March 9, 2013
Imprint: Springer Language: English
Author:
ISBN: 9783642815652
Publisher: Springer Berlin Heidelberg
Publication: March 9, 2013
Imprint: Springer
Language: English

The Analog Potential in Cancer Chemotherapy in the United States and Japan S. K. Carter Northern California Cancer Program, 1801 Page Mill Road, Building B, Suite 200, USA - Palo Alto, CA 94304 The bilateral collaborative program in cancer research between Japan and the United States is one of the oldest programs of this type. It is sponsored in the United States by the National Cancer Institute [1], while in Japan the sponsoring organization is the Japan Society for the Promotion of Science. Annual symposia concerning treatment have been held and in recent years they have been published [2, 3]. Drug development in both Japan and the United States has evolved over the years to an increasing emphasis on second generation compounds. This has come about as a result of the initial successes of chemotherapy development. Many active structures have been uncovered and the armamentarium of the medical and pediatric oncologist has grown dramatically. The uncovering of an active structure provides an opportunity for analog synthesis and attempts at elucidating structure-activity relationships. It is hoped that the therapeutic index of active structures can be improved so as to achieve superior clinical results.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

The Analog Potential in Cancer Chemotherapy in the United States and Japan S. K. Carter Northern California Cancer Program, 1801 Page Mill Road, Building B, Suite 200, USA - Palo Alto, CA 94304 The bilateral collaborative program in cancer research between Japan and the United States is one of the oldest programs of this type. It is sponsored in the United States by the National Cancer Institute [1], while in Japan the sponsoring organization is the Japan Society for the Promotion of Science. Annual symposia concerning treatment have been held and in recent years they have been published [2, 3]. Drug development in both Japan and the United States has evolved over the years to an increasing emphasis on second generation compounds. This has come about as a result of the initial successes of chemotherapy development. Many active structures have been uncovered and the armamentarium of the medical and pediatric oncologist has grown dramatically. The uncovering of an active structure provides an opportunity for analog synthesis and attempts at elucidating structure-activity relationships. It is hoped that the therapeutic index of active structures can be improved so as to achieve superior clinical results.

More books from Springer Berlin Heidelberg

Cover of the book Resonant X-Ray Scattering in Correlated Systems by
Cover of the book Strafprozessrecht - Schnell erfasst by
Cover of the book Let's do IT by
Cover of the book Applied Acoustics: Concepts, Absorbers, and Silencers for Acoustical Comfort and Noise Control by
Cover of the book Organometallics and Renewables by
Cover of the book Biogas Systems in China by
Cover of the book Advances in Natural Polymers by
Cover of the book Mathematik für Ingenieure: Verstehen – Rechnen – Anwenden by
Cover of the book Ocular Blood Flow by
Cover of the book Silicon Polymers by
Cover of the book Medizinische Statistik mit R und Excel by
Cover of the book Rock Grouting by
Cover of the book Coalgebraic Methods in Computer Science by
Cover of the book MRI of Cardiovascular Malformations by
Cover of the book Cardiomyopathies by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy